AI Article Synopsis
- The study focused on FLT3 mRNA expression in bone marrow samples from 85 acute myeloid leukemia (AML) patients, including 23 in complete remission.
- Researchers evaluated the potential of FLT3 as a marker for minimal residual disease (MRD) and its prognostic value.
- The findings suggest that FLT3 expression has limited effectiveness for both monitoring MRD and predicting patient outcomes.
Article Abstract
We studied wild-type FLT3 mRNA expression at diagnosis in bone marrow samples from 85 patients with acute myeloid leukemia (AML), 23 of whom were in complete remission, and determined its utility as a marker for minimal residual disease (MRD). We conclude that FLT3 expression is of limited value as a prognostic marker and for MRD monitoring.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
flt3 mrna
8
mrna expression
8
bone marrow
8
patients acute
8
acute myeloid
8
myeloid leukemia
8
limited flt3
4
expression bone
4
marrow prognosis
4
prognosis monitoring
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!